Kenvue (KVUE) is mulling the sale of some of its skin health and beauty brands as the management looks to prune some of its underperforming business assets to focus on core products, Reuters reports, citing people familiar with the matter. Kenvue plans to hold onto the bigger names, such as Neutrogena and Aveeno, the report states.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue Inc call volume above normal and directionally bullish
- Positive Outlook for Kenvue, Inc.: Stability Amid Challenges and Growth Opportunities
- Strategic Expansion of Kenvue, Inc. into the Supplements Market with Tylenol Brand
- Kenvue Inc. Shareholders Approve Key Proposals at 2025 Meeting
- Kenvue Inc. Completes $750 Million Senior Notes Offering
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue